These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 27864413)

  • 1. Cohort Profile: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord.
    Chêne G; Phillips A; Costagliola D; Sterne JAC; Furrer H; Del Amo J; Mocroft A; d'Arminio Monforte A; Dabis F; Miro JM; Barger D; Termote M; Schwimmer C; Salbøl Brandt R; Friis-Moller N; Raben D; Haerry D; Egger M; Weller I; De Wit S
    Int J Epidemiol; 2017 Jun; 46(3):797-797n. PubMed ID: 27864413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-naïve patients.
    Bouteloup V; Sabin C; Mocroft A; Gras L; Pantazis N; Le Moing V; d'Arminio Monforte A; Mary-Krause M; Roca B; Miro JM; Battegay M; Brockmeyer N; Berenguer J; Morlat P; Obel N; De Wit S; Fätkenheuer G; Zangerle R; Ghosn J; Pérez-Hoyos S; Campbell M; Prins M; Chêne G; Meyer L; Dorrucci M; Torti C; Thiébaut R;
    HIV Med; 2017 Jan; 18(1):33-44. PubMed ID: 27625009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunological and virological response to antiretroviral treatment in migrant and native men and women in Western Europe; is benefit equal for all?
    Migrant Health Working Group for the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord
    HIV Med; 2018 Jan; 19(1):42-48. PubMed ID: 28741837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Why START? Reflections that led to the conduct of this large long-term strategic HIV trial.
    ; Lundgren J; Babiker A; Gordin F; Emery S; Fätkenheuer G; Molina JM; Wood R; Neaton JD
    HIV Med; 2015 Apr; 16 Suppl 1(0 1):1-9. PubMed ID: 25711317
    [No Abstract]   [Full Text] [Related]  

  • 5. Delayed HIV diagnosis and initiation of antiretroviral therapy: inequalities by educational level, COHERE in EuroCoord.
    ; Lodi S; Dray-Spira R; Touloumi G; Braun D; Teira R; D'Arminio Monforte A; Gallois A; Zangerle R; Spire B; Dabis F; Stähelin C; Termote M; Kirk O; Chêne G; Egger M; del Amo J
    AIDS; 2014 Sep; 28(15):2297-306. PubMed ID: 25313585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of life after starting highly active antiretroviral therapy for chronic HIV-1 infection at different CD4 cell counts.
    Nieuwkerk PT; Hillebrand-Haverkort ME; Vriesendorp R; Frissen PH; de Wolf F; Sprangers MA;
    J Acquir Immune Defic Syndr; 2007 Aug; 45(5):600-1. PubMed ID: 17704686
    [No Abstract]   [Full Text] [Related]  

  • 7. Antiretroviral therapy recommendations for the global community: aspiration versus reality.
    Phillips AN; Munderi P; Revill PA; El-Sadr WM; Lundgren JD
    AIDS; 2014 Apr; 28(7):939-41. PubMed ID: 24378756
    [No Abstract]   [Full Text] [Related]  

  • 8. Mortality by baseline CD4 cell count among HIV patients initiating antiretroviral therapy: evidence from a large cohort in Uganda.
    Mills EJ; Bakanda C; Birungi J; Mwesigwa R; Chan K; Ford N; Hogg RS; Cooper C
    AIDS; 2011 Mar; 25(6):851-5. PubMed ID: 21330903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cohort Profile: Antiretroviral Therapy in Lower Income Countries (ART-LINC): international collaboration of treatment cohorts.
    Dabis F; Balestre E; Braitstein P; Miotti P; Brinkhof WG; Schneider M; Schechter M; Laurent C; Boulle A; Kabugo C; Capkun G; Seyler C; McIntyre J; Sprinz E; Bangsberg D; Van der Borght S; Egger M;
    Int J Epidemiol; 2005 Oct; 34(5):979-86. PubMed ID: 16157617
    [No Abstract]   [Full Text] [Related]  

  • 10. Impaired recovery of CD4+ cell counts following highly active antiretroviral therapy in drug-naïve patients coinfected with human immunodeficiency virus and hepatitis C virus.
    Macías J; Pineda JA; Lozano F; Corzo JE; Ramos A; León E; García-García JA; Fernández-Rivera J; Mira JA; Gómez-Mateos J
    Eur J Clin Microbiol Infect Dis; 2003 Nov; 22(11):675-80. PubMed ID: 14574616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Multi-State Model Examining Patterns of Transitioning Among States of Engagement in Care in HIV-Positive Individuals Initiating Combination Antiretroviral Therapy.
    Gillis J; Loutfy M; Bayoumi AM; Antoniou T; Burchell AN; Walmsley S; Cooper C; Klein MB; Machouf N; Montaner JS; Rourke SB; Tsoukas C; Hogg R; Raboud J;
    J Acquir Immune Defic Syndr; 2016 Dec; 73(5):531-539. PubMed ID: 27851713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 superinfection with a triple-class drug-resistant strain in a patient successfully controlled with antiretroviral treatment.
    Castro E; Zhao H; Cavassini M; Mullins JI; Pantaleo G; Bart PA
    AIDS; 2014 Jul; 28(12):1840-4. PubMed ID: 24911350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absolute count and percentage of CD4+ lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapy.
    Hulgan T; Shepherd BE; Raffanti SP; Fusco JS; Beckerman R; Barkanic G; Sterling TR
    J Infect Dis; 2007 Feb; 195(3):425-31. PubMed ID: 17205482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE).
    Mocroft A; Lundgren JD; Sabin ML; Monforte Ad; Brockmeyer N; Casabona J; Castagna A; Costagliola D; Dabis F; De Wit S; Fätkenheuer G; Furrer H; Johnson AM; Lazanas MK; Leport C; Moreno S; Obel N; Post FA; Reekie J; Reiss P; Sabin C; Skaletz-Rorowski A; Suarez-Lozano I; Torti C; Warszawski J; Zangerle R; Fabre-Colin C; Kjaer J; Chene G; Grarup J; Kirk O;
    PLoS Med; 2013; 10(9):e1001510. PubMed ID: 24137103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013.
    ; Mocroft A; Lundgren J; Antinori A; Monforte Ad; Brännström J; Bonnet F; Brockmeyer N; Casabona J; Castagna A; Costagliola D; De Wit S; Fätkenheuer G; Furrer H; Jadand C; Johnson A; Lazanas M; Leport C; Moreno S; Mussini C; Obel N; Post F; Reiss P; Sabin C; Skaletz-Rorowski A; Suarez-Loano I; Torti C; Warszawski J; Wittkop L; Zangerle R; Chene G; Raben D; Kirk O
    Euro Surveill; 2015; 20(47):. PubMed ID: 26624933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Timing of initiation of antiretroviral therapy in HIV-1-infected patients. Meta-analysis of the When To Start Consortium].
    Goebel FD; Nitschmann S
    Internist (Berl); 2010 Apr; 51(4):539-41. PubMed ID: 20237749
    [No Abstract]   [Full Text] [Related]  

  • 17. Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium.
    Bansi-Matharu L; Phillips A; Oprea C; Grabmeier-Pfistershammer K; Günthard HF; De Wit S; Guaraldi G; Vehreschild JJ; Wit F; Law M; Wasmuth JC; Chkhartishvili N; d'Arminio Monforte A; Fontas E; Vesterbacka J; Miro JM; Castagna A; Stephan C; Llibre JM; Neesgaard B; Greenberg L; Smith C; Kirk O; Duvivier C; Dragovic G; Lundgren J; Dedes N; Knudsen A; Gallant J; Vannappagari V; Peters L; Elbirt D; Sarcletti M; Braun DL; Necsoi C; Mussini C; Muccini C; Bolokadze N; Hoy J; Mocroft A; Ryom L
    Lancet HIV; 2021 Nov; 8(11):e711-e722. PubMed ID: 34555326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies.
    ; Sterne JA; May M; Costagliola D; de Wolf F; Phillips AN; Harris R; Funk MJ; Geskus RB; Gill J; Dabis F; Miró JM; Justice AC; Ledergerber B; Fätkenheuer G; Hogg RS; Monforte AD; Saag M; Smith C; Staszewski S; Egger M; Cole SR
    Lancet; 2009 Apr; 373(9672):1352-63. PubMed ID: 19361855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized controlled trial comparing the effects of counseling and alarm device on HAART adherence and virologic outcomes.
    Chung MH; Richardson BA; Tapia K; Benki-Nugent S; Kiarie JN; Simoni JM; Overbaugh J; Attwa M; John-Stewart GC
    PLoS Med; 2011 Mar; 8(3):e1000422. PubMed ID: 21390262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B and C Co-Infection in HIV Patients from the TREAT Asia HIV Observational Database: Analysis of Risk Factors and Survival.
    Chen M; Wong WW; Law MG; Kiertiburanakul S; Yunihastuti E; Merati TP; Lim PL; Chaiwarith R; Phanuphak P; Lee MP; Kumarasamy N; Saphonn V; Ditangco R; Sim BL; Nguyen KV; Pujari S; Kamarulzaman A; Zhang F; Pham TT; Choi JY; Oka S; Kantipong P; Mustafa M; Ratanasuwan W; Durier N; Chen YM
    PLoS One; 2016; 11(3):e0150512. PubMed ID: 26933963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.